Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kerr, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerr, K. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 587-591
© 1999 The British Society for Antimicrobial Chemotherapy

Leading article

The prophylaxis of bacterial infections in neutropenic patients

Kevin G. Kerr*

Department of Microbiology, University of Leeds, Leeds LS2 9JT, UK

Bacterial sepsis remains a major cause of morbidity and mortality in patients rendered neutropenic following cytoreductive therapy for haematological malignancy. The introduction of more aggressive anti-neoplastic chemotherapeutic regimes in individuals with solid organ malignancies has resulted in increasing numbers of these patients experiencing the profound neutropenia (i.e. granulocyte counts of<0.1x 109/L) that puts them at risk of infection. It is now over 30 years since Bodey et al., in a landmark paper,1 first quantified the risk of infection associated with severe neutropenia. Throughout this period much effort and considerable economic resources have been expended on developing effective approaches to prevent infection by bacteria and other microorganisms in this setting. Many of these strategies have fallen out of favour, having foundered on grounds of expense, patient unacceptability and consequent problems with compliance, and a lack of convincing scientific evidence to support their efficacy. One practice that has proved more . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
P. A. Masters, T. A. O'Bryan, J. Zurlo, D. Q. Miller, and N. Joshi
Trimethoprim-Sulfamethoxazole-Induced Life-Threatening Agranulocytosis--Reply
Arch Intern Med, September 8, 2003; 163(16): 1976 - 1976.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
P. A. Masters, T. A. O'Bryan, J. Zurlo, D. Q. Miller, and N. Joshi
Trimethoprim-Sulfamethoxazole Revisited
Arch Intern Med, February 24, 2003; 163(4): 402 - 410.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
E. Wang, N. Ouellet, M. Simard, I. Fillion, Y. Bergeron, D. Beauchamp, and M. G. Bergeron
Pulmonary and Systemic Host Response to Streptococcus pneumoniae and Klebsiella pneumoniae Bacteremia in Normal and Immunosuppressed Mice
Infect. Immun., September 1, 2001; 69(9): 5294 - 5304.
[Abstract] [Full Text] [PDF]